Onyx Biotec Limited — Others, 28-05-2025: Statement of deviation(s) or variation(s) under Reg. 32

Onyx Biotec Ltd. has announced no deviation in using its IPO proceeds, fully meeting its planned objectives: upgrading manufacturing Unit I for large-volume parentals, installing a high-speed packaging line at Unit II, loan repayment, and corporate purposes. The company raised ₹25.38 Cr net of expenses, slightly higher than initially expected. Utilization includes ₹12 Cr for loan repayment and ₹5.89 Cr for corporate needs. An advance payment of ₹60 lakh made in May 2025 is pending accounting. This disciplined use of funds supports operational growth and financial strengthening.